Volume 28, Issue 2 - Generics and biosimilars

Biosimilars: Change, challenge, and accomplishments

Author: Martin Mewies

Abstract

Download the full article

References

1. World Health Organization. Guidelines on evaluation of similar Biotherapeutic Products (SBPs), Annex 2, Technical Report Series No. 977, 2009 [cited 2019 Mar 10]. Available from: Available from: https://www.who.int/biologicals/ biotherapeutics/similar_biotherapeutic_ products/en/.
2. European Medicines Agency. Guideline on similar biological medicinal products, CHMP/437/04 Rev 1 [cited 2019 Mar 10]. Available from: Available from: https://www.ema.europa.eu/en/document s/scientific-guideline/guideline-similarbiological- medicinal-products-rev1_en.pdf.
3. Sarpatwari A, Barenie R, Curfman G, Darrow JJ, Kesselhein AS. The US Biosimilar Market: Stunted Growth and Possible Reforms. Am Soc Clin Pharmacol and Ther. 2019;105(1):92–100
4. Curto A. Trends and challenges in bio - similars pricing and reimbursement policies in Europe and beyond. Generics and Biosimilars Initiative J. 2017;6(2): 56–7
5. European Medicines Agency. Medicines [cited 2019 Mar 10]. Available from: Available from: https://www.ema.europa.eu/en/ medicines.
6. U. S. Food & Drug Administration (FDA). Biosimilar Product Information [cited 2019 Mar 10]. Available from: Available from: https://www.fda.gov/drugs/ developmentapprovalprocess/ howdrugsaredevelopedandapproved/ approvalapplications/therapeuticbiologic applications/biosimilars/ucm580432.htm.
7. Generics and Biosimilars Initiative Online. Guidelines for biosimilars around the world, posted 13 April 2018 [cited 2019 Mar 10]. Available from: Available from: http://www.gabionline.net/Reports/ Guidelines-for-biosimilars-around-theworld.
8. Generics and Biosimilars Initiative Online. Biosimilars in emerging markets, posted 19 Sept 2014 [cited 2019 Mar 10]. Available from: Available from: http://www.gabionline. net/Reports/ Biosimilars-in-emergingmarkets.
9. QuintilesIMS. The impact of biosimilar competition in Europe, published 5 May 2017 [cited 2019 Mar 10]. Available from: Available from: https://ec.europa.eu/ growth/content/ impact-biosimilar-competition-price-volumeand- market-share-update-2017–0_en.
10. European Medicines Agency. Neulasta: EPAR – Product Information. 2018.
11. Roche. MabThera SC/Rituxan Hycela™ (rituximab/hyaluronidase human) [cited 2019 Mar 14]. Available from: Available from: https://www.roche.com/products/ product-details.htm?productId=8abc3f49- f39f-4c6e-93ae-235c95c7efc6.
12. Tesser JRP, Furst DE, Jacobs I. Biosimilars and the extrapolation of indications for inflammatory conditions. Biologics. 2017;11:5–11.
13. U. S. Food & Drug Administration (FDA). Considerations in Demonstrating Interchangeability With a Reference Product, Draft Guidance, January 2017 [cited 2019 Mar 10]. Available from: Available from: https://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatory Information/Guidances/UCM537135.pdf.
14. U. S. Food & Drug Administration (FDA). Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations, [cited 2019 Mar 10]. Available from: Available from: https://www.fda.gov/drugs/development approvalprocess/howdrugsaredeveloped andapproved/approvalapplications/ therapeuticbiologic applications/ biosimilars/ucm411418.htm.
15. U. S. Food & Drug Administration (FDA). Statement from FDA Commissioner Scott Gottlieb, M.D., on FDA’s steps on naming of biological medicines to balance competition and safety for patients receiving these products, 7 March 2019 [cited 2019 Mar 10]. Available from: Available from: https://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ ucm632870.htm.